Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 13/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567045 | 1.00 | SMYD3 (0.57) | SMYD3AHRHDAC3EPHX2SIRT2 | |
| Hydrochloric Acid SCHEMBL28849276 | 0.98 | SMYD3 (0.56) | SMYD3AHRHDAC3EPHX2SIRT2 | |
| SCHEMBL3581228 | 0.91 | SMYD3 (0.55) | SMYD3AHRHDAC3EPHX2 | |
| SCHEMBL3575509 | 0.90 | SMYD3 (0.52) | SMYD3AHRHDAC3EPHX2TDP2 | |
| SCHEMBL3194345 | 0.88 | SMYD3 (0.58) | SMYD3AHRHDAC3TDP2 | |
| SCHEMBL30760741 | 0.88 | SMYD3 (0.58) | SMYD3AHRHDAC3TDP2 | |
| Hydrochloric Acid SCHEMBL29528151 | 0.86 | SMYD3 (0.57) | SMYD3AHRHDAC3TDP2 | |
| SCHEMBL9375237 | 0.85 | SIRT2 (0.61) | SMYD3HDAC3SIRT2 | |
| SCHEMBL688890 | 0.84 | TDP2 (0.61) | SMYD3AHRHDAC3EPHX2TDP2 | |
| SCHEMBL29899624 | 0.84 | TDP2 (0.72) | AHRTDP2GRIA1CACNG8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225735-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | claimed |
| CN-116457346-A | Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2022076496-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | claimed |
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025064829-A1 | A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-111801322-B | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2024-03-15 | — | — | CN | disclosed |
| EP-4225735-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116457346-A | Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4157858-A2 | SMALL MOLECULE INHIBITORS OF GRK5 AND GRK5 SUBFAMILY MEMBERS AND USES THEREOF | The Regents of The University of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2022076496-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | disclosed |
| US-5019587-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-28 | — | — | US | disclosed |
| CN-1038640-A | Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-10 | — | — | CN | disclosed |
| EP-0344634-A1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885AHR 2482/4885HDAC3 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.